As part of its commitment to meet the needs of patients in the region, Sanofi held the second edition of its annual conference on immune infections of the second type, which brought together 15 experts in the field from all over the world, to discuss developments in treatment methods, and share the best local and international practices in diagnosing And cure this type of disease.
The two-day virtual summit was attended by more than 520 healthcare professionals and practitioners from various sectors in the region.
Type 2 infections are part of the immune system’s defenses against allergens, but if they are aggravated, they can cause severe itching in patients with atopic dermatitis, severe asthma attacks that may be unpredictable, and loss of smell and taste associated with acute chronic sinusitis with disease Nasal polyps.
Type 2 infections can also negatively affect both physical and psychological health, as those with moderate to severe infections suffer from sleep disturbances and poor mental state.
Studies indicate that:
• Approximately 46% of adolescents with atopic dermatitis have their school life negatively affected.
• 50% of people with severe asthma have developed depression.
• More than 90% of people with chronic sinusitis with “nasal polyps” are unable to sleep comfortably.
In this regard, Dr. Essam Hamadeh, a dermatologist at King Faisal Specialist Hospital and Research Center, referred to atopic dermatitis (eczema), which is among the most common immune infections, in which sufferers suffer from severe itching and skin disorders. According to a study published in the American Journal of Managed Care in 2019, this chronic skin condition affects 15 to 20 percent of children and 1 to 3 percent of adults around the world. The study also indicates that atopic dermatitis can have a physical, emotional, psychological and social impact, causing sleep disturbance, anxiety, depression, and feelings of isolation. For his part, Dr. Majid Idris, Assistant Professor of Pulmonology at the University of British Columbia, highlighted the type 2 asthma disease that affects more than 300 million people worldwide, and whose sufferers suffer from shortness of breath, wheezing and coughing.
“Patients with severe asthma often have severe, unpredictable attacks,” he said. They also face, in most cases, financial distress resulting from the high costs of treatment and limited professional options. ”
On the other hand, immune disorders greatly affect the nose, eyes, skin and lungs. These disorders include conjunctivitis, external atopic dermatitis (the most common type of eczema), immune urticaria, immune angioedema, acute latex allergy, some allergic lung disorders, allergic rhinitis, and allergic reactions to toxic stings. Dr. Rand Al-Arnaout, Head of the Department of Allergy and Immunology at King Faisal Specialist Hospital in the Kingdom of Saudi Arabia, said that these diseases constitute a heavy burden on the health sector, as they affect millions of individuals around the world, especially children and youth.
Most of the time a person may have more than one atopic disease at the same time, which confirms the need to improve and develop the process of diagnosis and treatment that would benefit both patients and doctors. Dr. Hussain Al-Rand, the consultant head of the otolaryngology department and the otolaryngology division at the Emirates Medical Association, the regional secretary of the International Federation of Otolaryngological Societies for the Middle East and the Gulf, pointed out that the main cause of chronic sinusitis with “nasal polyps” is unknown, but Most of the time, a biopsy of the tissues of the adenoids reveals allergic cells called “eosinophils”, and usually the average age of people with this condition is between 30 and 40.
“Symptoms of chronic sinusitis with” nasal polyps “may affect sleep quality, as it causes snoring and shortness of breath, in addition to mood swings, fatigue and depression, Al Rand said. These symptoms also affect the individual’s productivity at work and his daily activity with the inability to enjoy food and smell the smell of smoke or fires.
Jean-Paul Scheuer, President and General Manager of Sanofi Gulf Region, expressed his gratitude to the experts in raising awareness about type 2 immune infections. “We appreciate the great efforts made by the experts to participate in such important summits, as they played a vital role in leading the discussion about the guidelines. “They dealt with the treatment protocols that helped enhance the knowledge and capabilities of health care professionals, which will benefit patients.”